alexa Impact of 11C-choline PET CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial.


Journal of Nuclear Medicine & Radiation Therapy

Author(s): Ceci F, Herrmann K, Castellucci P, Graziani T, Bluemel C,

Abstract Share this page

Abstract PURPOSE: The aim of this retrospective two-centre study was to investigate the clinical impact of (11)C-choline PET/CT on treatment management decisions in patients with recurrent prostate cancer (rPCa) after radical therapy. METHODS: Enrolled in this retrospective study were 150 patients (95 from Bologna, 55 from Würzburg) with rPCa and biochemical relapse (PSA mean ± SD 4.3 ± 5.5 ng/mL, range 0.2-39.4 ng/mL) after radical therapy. The intended treatment before PET/CT was salvage radiotherapy of the prostatic bed in 95 patients and palliative androgen deprivation therapy (ADT) in 55 patients. The effective clinical impact of (11)C-choline PET/CT was rated as major (change in therapeutic approach), minor (same treatment, but modified therapeutic strategy) or none. Multivariate binary logistic regression analysis included PSA level, PSA kinetics, ongoing ADT, Gleason score, TNM, age and time to relapse. RESULTS: Changes in therapy after (11)C-choline PET/CT were implemented in 70 of the 150 patients (46.7\%). A major clinical impact was observed in 27 patients (18\%) and a minor clinical impact in 43 (28.7\%). (11)C-choline PET/CT was positive in 109 patients (72.7\%) detecting local relapse (prostate bed and/or iliac lymph nodes and/or pararectal lymph nodes) in 64 patients (42.7\%). Distant relapse (paraaortic and/or retroperitoneal lymph nodes and/or bone lesions) was seen in 31 patients (20.7\%), and both local and distant relapse in 14 (9.3\%). A significant difference was observed in PSA level and PSA kinetics between PET-positive and PET-negative patients (p < 0.05). In multivariate analysis, PSA level, PSA doubling time and ongoing ADT were significant predictors of a positive scan (p < 0.05). In statistical analysis no significant differences were observed between the Bologna and Würzburg patients (p > 0.05). In both centres the same criteria to validate PET-positive findings were used: in 17.3\% of patients by histology and in 82.7\% of patients by correlative imaging and/or clinical follow-up (follow-up mean 20.5 months, median 18.3 months, range 6.2-60 months). CONCLUSION: (11)C-Choline PET/CT had a significant impact on therapeutic management in rPCa patients. It led to an overall change in 46.7\% of patients, with a major clinical change implemented in 18\% of patients. Further prospective studies are needed to evaluate the effect of such treatment changes on patient survival. This article was published in Eur J Nucl Med Mol Imaging and referenced in Journal of Nuclear Medicine & Radiation Therapy

Relevant Expert PPTs

Relevant Speaker PPTs

  • Eugene Stephane Mananga
    On Fer and Floquet-Magnus expansions: Application in solid-state nuclear magnetic resonance and physics
    PDF Version
  • Qian Zeng
    A New Anti-inflammatory Therapy for COPD
    PDF Version
  • Rongtuan Lin
    Modulating the Antioxidant Defences to Potentiate Oncolytic Virotherapy in Refractory Cancer Cells
    PPT Version | PDF Version
  • Vicky Stewart
    Clinical Effectiveness of Physiotherapy-led Vestibular Service in tertiary hospital
    PPT Version | PDF Version
  • Ganapathi Bhat Mugulthimoole
    Unmasking the masquerading cancer cells: have we made progress with the revival of immunotherapy?
    PPT Version | PDF Version
  • Moshe Giladi
    Tumor Treating Fields (TTFields) induced cancer cell death may be immunogenic resulting in enhanced antitumor efficacy when combined with immune-modulating therapy
    PPT Version | PDF Version
  • Roger Mark Engel
    The effect of including manual therapy in the management of mild chronic obstructive pulmonary disease – a randomized controlled trial
    PDF Version
  • Mervi Siekkinen
    Effect of e-feedback on knowledge about radiotherapy of breast cancer patients
    PPT Version | PDF Version
  • Inge Verbrugge
    Radio-immunotherapy of cancer: Therapeutic efficacy, underlying mechanisms and potential applications
    PPT Version | PDF Version
  • Sitanshu Sekhar Lahiri
    A novel oral formulation for cancer therapy, loaded in a slow release matrix for targeted delivery
    PPT Version | PDF Version
  • Ehab Kamal
    Apitherapy in immune mediated disorders
    PPT Version | PDF Version
  • Toshimasa Nakada
    Usefulness of initial single intravenous immunoglobulin therapy for Kawasaki disease
    PPT Version | PDF Version
  • Geeta Shroff
    Improved Epilepsy and Speech Outcomes with Human Embryonic Stem Cell Therapy in Children with Cerebral Palsy
    PPT Version | PDF Version
  • Yosef Yarden
    Classically, the 3’untranslated region (3’UTR) is that region in eukaryotic protein-coding genes from the translation termination codon to the polyA signal. It is transcribed as an integral part of the mRNA encoded by the gene. However, there exists another kind of RNA, which consists of the 3’UTR alone, without all other elements in mRNA such as 5’UTR and coding region. The importance of independent 3’UTR RNA (referred as I3’UTR) was prompted by results of artificially introducing such RNA species into malignant mammalian cells. Since 1991, we found that the middle part of the 3’UTR of the human nuclear factor for interleukin-6 (NF-IL6) or C/EBP gene exerted tumor suppression effect in vivo. Our subsequent studies showed that transfection of C/EBP 3’UTR led to down-regulation of several genes favorable for malignancy and to up-regulation of some genes favorable for phenotypic reversion. Also, it was shown that the sequences near the termini of the C/EBP 3’UTR were important for its tumor suppression activity. Then, the C/EBP 3’UTR was found to directly inhibit the phosphorylation activity of protein kinase CPKC in SMMC-7721, a hepatocarcinoma cell line. Recently, an AU-rich region in the C/EBP 3’UTR was found also to be responsible for its tumor suppression. Recently we have also found evidence that the independent C/EBP 3’UTR RNA is actually exists in human tissues, such as fetal liver and heart, pregnant uterus, senescent fibroblasts etc. Through 1990’s to 2000’s, world scientists found several 3’UTR RNAs that functioned as artificial independent RNAs in cancer cells and resulted in tumor suppression. Interestingly, majority of genes for these RNAs have promoter-like structures in their 3’UTR regions, although the existence of their transcribed products as independent 3’UTR RNAs is still to be confirmed. Our studies indicate that the independent 3’UTR RNA is a novel non-coding RNA species whose function should be the regulation not of the expression of their original mRNA, but of some essential life activities of the cell as a whole.
    PPT Version | PDF Version
  • Rupal Patel Mansukhani
    Correlation of Medication Therapy in Chronic Obstructive Pulmonary Disease(COPD) Patients with 30-day Readmission Rates
    PPT Version | PDF Version

Recommended Conferences

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version